Date:7/18/2011

storical facts are forward-looking statements. Such forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, the Company's results could be materially adversely affected. The risks and uncertainties include, but are not limited to, risks associated with: the inherent uncertainty of research, development, approval, reimbursement, manufacturing and commercialization of the Company's Specialty Pharmaceuticals and Human Genetic Therapies products, as well as the ability to secure and integrate new products for commercialization and/or development; government regulation of the Company's products; the Company's ability to manufacture its products in sufficient quantities to meet demand; the impact of competitive therapies on the Company's products; the Company's ability to register, maintain and enforce patents and other intellectual property rights relating to its products; the Company's ability to obtain and maintain government and other third-party reimbursement for its products; and other risks and uncertainties detailed from time to time in the Company's filings with the Securities and Exchange Commission.

For further information please contact:

Media

Matthew Cabrey (mcabrey@shire.com) +1-484-595-8248 Ingrid Jansen (ijansen@shire.com) +32-14-404-360 Meredith Butler (mbutler@golinharris.com) (GolinHarris for Shire) +1-919-381-6936

'/>"/>

SOURCE Shire plc Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5
Related medicine technology :

1. Shire plc : Second Quarter 2011 Results Date Notification - July 28, 2011
2. Shire Files Lawsuits Against Sandoz and Amneal for Infringement of VYVANSE® (lisdexamfetamine dimesylate) Patents
3. United Lincolnshire Hospitals NHS Trust Selects Jayex QI Interactive Patient Survey and Information Management Kiosk
4. Shire Completes Acquisition of Advanced BioHealing, Inc.
5. European Authorities Approve New Manufacturing Facility for Shires REPLAGAL® (agalsidase alfa)
6. Prasco Announces Agreement with Shire for Future Exclusive Distribution and Supply of Authorized Generic for PENTASA®
7. Shire Recognized by ISPE Facility of the Year Awards Program
8. Reportlinker Adds Shire plc: PharmaVitae Profile
9. Shire Presents Positive New Data at the 60th Annual American Society of Human Genetics (ASHG) for Patients with Type 1 Gaucher Disease
10. Shire plc: Third Quarter 2010 Results Date Notification - October 29, 2010
11. Atrium Recognized by New Hampshire Bio/Medical Council